Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919512 · ClinicalTrials.gov registry record · Phase 2
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
A Phase 2 study of Urinary Bladder Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT04919512 is a Phase 2 study of Urinary Bladder Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 163 participants, below the 304-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04919512, a Phase 2 study of Urinary Bladder Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Conditions Studied
Interventions
- DRUG TAR-200
- BIOLOGICAL Cetrelimab
Study Locations (20)
Florida
- University of Florida Health Jacksonville - Jacksonville
- Mayo Clinic - Jacksonville
- Baptist Hospital of Miami - Miami
Arkansas
- UAMS Winthrop P. Rockefeller Cancer Institute - Little Rock
- Arkansas Urology - Little Rock
California
- City of Hope - Duarte
- Genesis Research - San Diego
Indiana
- Urology of Indiana - Indianapolis
- First Urology - Jeffersonville
Maryland
- University Of Maryland Medical Center - Baltimore
- Penn Medicine - PerelmanCenter for Advanced Medicine - Baltimore
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Urological Associates of Southern Arizona, P.C. - Tucson
Colorado
- Colorodo Urology- St. Anthony Hospital - Golden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2027-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919512
The ClinicalTrials.gov registry entry for NCT04919512 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target (46% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Bladder Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which TAR-200 is the first listed.
NCT04919512 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT04919512 about?
NCT04919512 is a clinical study titled "A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder". The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
What is the current status of trial NCT04919512?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2022-07-07. Estimated completion is 2027-03-07.
What conditions does trial NCT04919512 study?
This clinical trial studies the following conditions: Urinary Bladder Neoplasms.
What interventions are being tested in trial NCT04919512?
The interventions under investigation include: TAR-200 (DRUG), Cetrelimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04919512?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919512 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Bladder Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
RECRUITING · Phase 2
-
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
ACTIVE NOT RECRUITING · Phase 2
-
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
COMPLETED · Phase 2
-
Cabozantinib for Advanced Urothelial Cancer
COMPLETED · Phase 2
-
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.